Literature DB >> 7514184

Vascular cell adhesion molecule-1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis.

D M Barten1, N H Ruddle.   

Abstract

Anti-tumor necrosis factor (TNF) antibodies inhibit passively transferred experimental allergic encephalomyelitis (EAE) in SJL mice. The possibility that this occurs through interference in TNF's upregulation of endothelial cell adhesion molecules was investigated. Expression of both vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) on spinal cord vessels increased during EAE. The upregulation of VCAM-1 was markedly reduced or prevented by anti-TNF treatment. Leukocytic infiltration was 15-fold lower in anti-TNF-treated than diseased animals. Spinal cord endothelial expression of VCAM-1, though not ICAM-1 or fibronectin, positively correlated with the extent of T cell, B cell or monocyte infiltration in each animal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514184     DOI: 10.1016/0165-5728(94)90074-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  16 in total

1.  The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

Authors:  B Bourrié; E Bribes; M Esclangon; L Garcia; J Marchand; C Thomas; J P Maffrand; P Casellas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 2.  Interaction between the immune and central nervous systems.

Authors:  John H Russell
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 3.  Pathophysiology of the blood-brain barrier.

Authors:  K Selmaj
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Cytokines, signal transduction, and inflammatory demyelination: review and hypothesis.

Authors:  R W Ledeen; G Chakraborty
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

5.  A tumor necrosis factor receptor 1-dependent conversation between central nervous system-specific T cells and the central nervous system is required for inflammatory infiltration of the spinal cord.

Authors:  Mary Ann Gimenez; Julia Sim; Angela S Archambault; Robyn S Klein; John H Russell
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

6.  Elevated interferon gamma expression in the central nervous system of tumour necrosis factor receptor 1-deficient mice with experimental autoimmune encephalomyelitis.

Authors:  Rachel D Wheeler; Simone P Zehntner; Lisa M Kelly; Lyne Bourbonnière; Trevor Owens
Journal:  Immunology       Date:  2006-06-16       Impact factor: 7.397

7.  Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis.

Authors:  H Körner; A L Goodsall; F A Lemckert; B J Scallon; J Ghrayeb; A L Ford; J D Sedgwick
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Sleep fragmentation and sepsis differentially impact blood-brain barrier integrity and transport of tumor necrosis factor-α in aging.

Authors:  Mark R Opp; Amrita George; Kristyn M Ringgold; Kim M Hansen; Kristin M Bullock; William A Banks
Journal:  Brain Behav Immun       Date:  2015-07-26       Impact factor: 7.217

9.  Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection.

Authors:  María Colmenares; Peter E Kima; Erika Samoff; Lynn Soong; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

10.  Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.

Authors:  C P Genain; T Roberts; R L Davis; M H Nguyen; A Uccelli; D Faulds; Y Li; J Hedgpeth; S L Hauser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.